Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | ALPG | P10696 | 1/20 | 0.30 |
| ▸ | GFER | P55789 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6990898 | 0.98 | GAA (0.33) | GAAALPGGFER | |
| SCHEMBL26078203 | 0.86 | CHRNA7 (0.32) | — | |
| SCHEMBL572684 | 0.80 | ACE (0.36) | — | |
| SCHEMBL5426630 | 0.78 | SMN1; SMN2 (0.33) | — | |
| Hydrochloric Acid SCHEMBL14343353 | 0.78 | ACE (0.35) | GAAALPGGFER | |
| Hydrochloric Acid SCHEMBL5473763 | 0.78 | ACE (0.35) | GAAALPGGFER | |
| Hydrochloric Acid SCHEMBL14343221 | 0.78 | ACE (0.35) | GAAALPGGFER | |
| SCHEMBL5433240 | 0.78 | SMN1; SMN2 (0.33) | — | |
| SCHEMBL30363259 | 0.78 | GAA (0.33) | GAAALPGGFER | |
| Bromide SCHEMBL28148076 | 0.78 | ACE (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118027066-A | Thienopyrimidinone compound, preparation method and application thereof | 厦门宝太生物科技股份有限公司 | 2024-05-14 | — | — | CN | disclosed |
| CN-111989331-B | Synthesis method of 2- [ (2S) -1-azabicyclo [2.2.2] oct-2-yl ] -6- (3-methyl-1H-pyrazol-4-yl) thieno [3,2-d ] pyrimidine-4 (3H) -ketone | 武田药品工业株式会社 | 2024-04-12 | — | — | CN | disclosed |
| US-20240025920-A1 | SALT FORM USED AS CDC7 INHIBITOR AND CRYSTAL FORM THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-20240025920-A1 | SALT FORM USED AS CDC7 INHIBITOR AND CRYSTAL FORM THEREOF | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2024-01-25 | — | — | US | disclosed |
| US-11524957-B2 | Process for the synthesis of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-13 | — | — | US | disclosed |
| US-11524957-B2 | Process for the synthesis of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-12-13 | — | — | US | disclosed |
| US-20220389026-A1 | TETRACYCLIC COMPOUND USED AS CDC7 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-12-08 | — | — | US | disclosed |
| EP-4006036-A1 | TETRACYCLIC COMPOUND USED AS CDC7 INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-06-01 | — | — | EP | disclosed |
| US-20210101897-A1 | PROCESS FOR THE SYNTHESIS OF 2-[(2S)-1-AZABICYCLO[2.2.2]OCT-2-YL]-6-(3-METHYL-1H-PYRAZOL-4-YL)THIENO[3,2-d]PYRIMIDIN-4(3H)-ONE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-08 | — | — | US | disclosed |
| US-20210101897-A1 | PROCESS FOR THE SYNTHESIS OF 2-[(2S)-1-AZABICYCLO[2.2.2]OCT-2-YL]-6-(3-METHYL-1H-PYRAZOL-4-YL)THIENO[3,2-d]PYRIMIDIN-4(3H)-ONE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-04-08 | — | — | US | disclosed |
| WO-2021032170-A1 | TETRACYCLIC COMPOUND USED AS CDC7 INHIBITOR | 南京明德新药研发有限公司 | 2021-02-25 | — | — | WO | disclosed |
| EP-3774816-A1 | PROCESS FOR THE SYNTHESIS OF 2-[(2S)-1-AZABICYCLO[2.2.2]OCT-2-YL]-6- (3-METHYL-1 H-PYRAZOL-4-YL)THIENO[3,2-D]PYRIMIDIN-4(3H)-ONE | Takeda Pharmaceutical Company Limited (JP) | 2021-02-17 | — | — | EP | disclosed |
| WO-2020239107-A1 | TETRACYCLIC COMPOUNDS AS CDC7 INHIBITORS | 正大天晴药业集团股份有限公司 | 2020-12-03 | — | — | WO | disclosed |
| CN-111989331-A | Synthesis method of 2- [ (2S) -1-azabicyclo [2.2.2] oct-2-yl ] -6- (3-methyl-1H-pyrazol-4-yl) thieno [3,2-d ] pyrimidine-4 (3H) -ketone | 武田药品工业株式会社 | 2020-11-24 | — | — | CN | disclosed |
| WO-2019194319-A1 | PROCESS FOR THE SYNTHESIS OF 2-[(2S)-1-AZABICYCLO[2.2.2]OCT-2-YL]-6- (3-METHYL-1 H-PYRAZOL-4-YL)THIENO[3,2-D]PYRIMIDIN-4(3H)-ONE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019194319-A1 | PROCESS FOR THE SYNTHESIS OF 2-[(2S)-1-AZABICYCLO[2.2.2]OCT-2-YL]-6- (3-METHYL-1 H-PYRAZOL-4-YL)THIENO[3,2-D]PYRIMIDIN-4(3H)-ONE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-10-10 | — | — | WO | disclosed |
| US-6468998-B1 | ANTAGONIZE SEROTONIN 2 RECEPTORS, SUPPRESS PLATELET AGGREGATION, IMPROVE PERIPHERAL CIRCULATION AND PROMOTE LACHRYMATION | MITSUBISHI PHARMA CORPORATION (JP) | 2002-10-22 | — | — | US | disclosed |
| EP-1125922-A1 | PYRROLIDINE COMPOUNDS AND MEDICINAL UTILIZATION THEREOF | Welfide Corporation (JP) | 2001-08-22 | — | — | EP | disclosed |
| US-4145414-A | ANTIVIRAL, IMMUNOSUPPRESSIVE, ANTILEUKEMIA | THE UPJOHN COMPANY (US) | 1979-03-20 | — | — | US | disclosed |
| US-4096324-A | ANTI-VIRAL, ANTILEUKEMIA | THE UPJOHN COMPANY (US) | 1978-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11524957-B2 | Process for the synthesis of 2-[(2S)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1H-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3H)-one | CDC7, CDK7, CDCA2 | GAA 3391/4885ALPG 2328/4885GFER 4788/4885 |
| US-20240025920-A1 | SALT FORM USED AS CDC7 INHIBITOR AND CRYSTAL FORM THEREOF | CDC7, CDC73, CDC5L | GAA 2287/4885ALPG 1795/4885GFER 3528/4885 |
| US-20210101897-A1 | PROCESS FOR THE SYNTHESIS OF 2-[(2S)-1-AZABICYCLO[2.2.2]OCT-2-YL]-6-(3-METHYL-1H-PYRAZOL-4-YL)THIENO[3,2-d]PYRIMIDIN-4(3H)-ONE | CDC7, CDK7, CDCA2 | GAA 3399/4885ALPG 2329/4885GFER 4788/4885 |
| US-20220389026-A1 | TETRACYCLIC COMPOUND USED AS CDC7 INHIBITOR | CDC7, CDC5L, CDC16 | GAA 2434/4885ALPG 2383/4885GFER 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.